// App-Quantinova.ai

3196 : Analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRLX301, a nanoparticle of docetaxel

Researchers

Presenter

  • Eiman Mukhtar

Principal Investigators

  • Daniel Worroll

  • Giuseppe Galletti

  • Shelly Schuster

  • Sarina A. Piha-Paul

  • Paraskevi Giannakakou

Medical Centers

  • Weill Cornell Medical College, New York, NY

  • NewLink Genetics Corporation, Ames, IA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

Drug/Treatment

  • Docetaxel

  • taxane

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved